Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Doosoo Jeon

Showing results (71-80 of 81) with videos related to

Pageof 9
Sort By:
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 2, 2024
Improvement in Health-Related Quality of Life Following Antibiotic Treatment in Nontuberculous Mycobacterial Pulmonary Disease: Initial Analysis of the NTM-KOREA CohortNakwon Kwak, Emily Henkle, Hyeontaek Hwang, et al.
Scientific Reports|April 30, 2026
Impact of vitamin D deficiency on 6-month culture conversion in nontuberculous mycobacterial pulmonary diseaseTae-Ok Kim, Nakwon Kwak, Doosoo Jeon, et al.
Scientific Reports|July 19, 2025
BACES score: a predictor of health-related quality of life and associated factors in patients with nontuberculous mycobacterial pulmonary diseaseYoungmok Park, Nakwon Kwak, Hyeontaek Hwang, et al.
Tuberculosis and Respiratory Diseases|September 29, 2024
High-Dose Rifampicin for 3 Months after Culture Conversion for Drug-Susceptible Pulmonary TuberculosisNakwon Kwak, Joong-Yub Kim, Hyung-Jun Kim, et al.
Journal of Clinical Microbiology|December 25, 2009
Polymorphisms associated with resistance and cross-resistance to aminoglycosides and capreomycin in Mycobacterium tuberculosis isolates from South Korean Patients with drug-resistant tuberculosisLaura E Via, Sang-Nae Cho, Soohee Hwang, et al.
Respiratory Research|February 21, 2026
Association between nutritional status and clinical characteristics in nontuberculous mycobacterial pulmonary disease: preliminary results from the NTM-KOREA cohortSungyoon Yang, Youngmok Park, Nakwon Kwak, et al.
Science Translational Medicine|December 5, 2014
PET/CT imaging correlates with treatment outcome in patients with multidrug-resistant tuberculosisRay Y Chen, Lori E Dodd, Myungsun Lee, et al.
Antimicrobial Agents and Chemotherapy|June 5, 2013
Efficacy and safety of metronidazole for pulmonary multidrug-resistant tuberculosisMatthew W Carroll, Doosoo Jeon, James M Mountz, et al.
Lancet (London, England)|December 15, 2022
9 months of delamanid, linezolid, levofloxacin, and pyrazinamide versus conventional therapy for treatment of fluoroquinolone-sensitive multidrug-resistant tuberculosis (MDR-END): a multicentre, randomised, open-label phase 2/3 non-inferiority trial in South KoreaJeongha Mok, Myungsun Lee, Deog Kyeom Kim, et al.
Trials|January 18, 2019
Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II/III, multicenter, randomized, open-label clinical trialMyungsun Lee, Jeongha Mok, Deog Kyeom Kim, et al.
Pageof 9

Showing results (71-80 of 81) with videos related to

Sort By:
Pageof 9
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 2, 2024
Improvement in Health-Related Quality of Life Following Antibiotic Treatment in Nontuberculous Mycobacterial Pulmonary Disease: Initial Analysis of the NTM-KOREA CohortNakwon Kwak, Emily Henkle, Hyeontaek Hwang, et al.
Scientific Reports|April 30, 2026
Impact of vitamin D deficiency on 6-month culture conversion in nontuberculous mycobacterial pulmonary diseaseTae-Ok Kim, Nakwon Kwak, Doosoo Jeon, et al.
Scientific Reports|July 19, 2025
BACES score: a predictor of health-related quality of life and associated factors in patients with nontuberculous mycobacterial pulmonary diseaseYoungmok Park, Nakwon Kwak, Hyeontaek Hwang, et al.
Tuberculosis and Respiratory Diseases|September 29, 2024
High-Dose Rifampicin for 3 Months after Culture Conversion for Drug-Susceptible Pulmonary TuberculosisNakwon Kwak, Joong-Yub Kim, Hyung-Jun Kim, et al.
Journal of Clinical Microbiology|December 25, 2009
Polymorphisms associated with resistance and cross-resistance to aminoglycosides and capreomycin in Mycobacterium tuberculosis isolates from South Korean Patients with drug-resistant tuberculosisLaura E Via, Sang-Nae Cho, Soohee Hwang, et al.
Respiratory Research|February 21, 2026
Association between nutritional status and clinical characteristics in nontuberculous mycobacterial pulmonary disease: preliminary results from the NTM-KOREA cohortSungyoon Yang, Youngmok Park, Nakwon Kwak, et al.
Science Translational Medicine|December 5, 2014
PET/CT imaging correlates with treatment outcome in patients with multidrug-resistant tuberculosisRay Y Chen, Lori E Dodd, Myungsun Lee, et al.
Antimicrobial Agents and Chemotherapy|June 5, 2013
Efficacy and safety of metronidazole for pulmonary multidrug-resistant tuberculosisMatthew W Carroll, Doosoo Jeon, James M Mountz, et al.
Lancet (London, England)|December 15, 2022
9 months of delamanid, linezolid, levofloxacin, and pyrazinamide versus conventional therapy for treatment of fluoroquinolone-sensitive multidrug-resistant tuberculosis (MDR-END): a multicentre, randomised, open-label phase 2/3 non-inferiority trial in South KoreaJeongha Mok, Myungsun Lee, Deog Kyeom Kim, et al.
Trials|January 18, 2019
Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II/III, multicenter, randomized, open-label clinical trialMyungsun Lee, Jeongha Mok, Deog Kyeom Kim, et al.
Pageof 9